Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group.

Partsch CJ, Heger S, Sippell WG

Journal of pediatric endocrinology & metabolism : JPEM1 Jul 2000Cited by 30 (Europe PMC)

PMID10969917DOI10.1515/jpem.2000.13.s1.747PepBankPUB-10969917

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In young women treated for central precocious puberty, final height after triptorelin exceeded initial predicted height.
In plain wordsIn young women treated for early puberty, final height after triptorelin exceeded the initial prediction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height versus initial prediction
Study
n = 52
Comparator
Initial predicted adult height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.8 +/- 2.2 yrAs given in this study (human).
Measurements
Final height
160.6 cm
after treatment
Initial predicted height
154.9 cm
before treatment
Source sentences
Summary
After 4.8 +/- 2.2 yr (1.1-9.9 yr) of treatment duration, FH was 160.6 +/- 8.0 cm (vs 154.9 +/- 9.6 cm of initial height prediction [PAH], p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the FH data of 52 young women from a prospective multicentric trial which was started in 1985.
Summary · context
Chronological age (CA) was 5.2 +/- 2.1 yr (+/- SD) at start of puberty, 6.2 +/- 2.0 yr at start of triptorelin depot treatment, 11.1 +/- 1.1 yr at end of treatment, and 16.7 +/- 2.6 yr at FH evaluation.
Report a problemFND-1096991701
02HumanNon-randomized trialEfficacy outcome
In young women treated with triptorelin for central precocious puberty, 78% achieved final height within the target-height range.
In plain wordsIn young women treated with triptorelin for early puberty, 78% achieved final height within the target range.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height within target range
Study
n = 52
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.8 +/- 2.2 yrAs given in this study (human).
Measurements
Within target-height range
78%
final height
Source sentences
Summary
A FH within TH range or in excess of mean TH was achieved by 78% or 41% of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the FH data of 52 young women from a prospective multicentric trial which was started in 1985.
Summary · context
Chronological age (CA) was 5.2 +/- 2.1 yr (+/- SD) at start of puberty, 6.2 +/- 2.0 yr at start of triptorelin depot treatment, 11.1 +/- 1.1 yr at end of treatment, and 16.7 +/- 2.6 yr at FH evaluation.
Report a problemFND-1096991702
03HumanNon-randomized trialEfficacy outcome
In young women treated with triptorelin for central precocious puberty, 41% exceeded mean target height.
In plain wordsIn young women treated with triptorelin for early puberty, 41% exceeded mean target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height exceeding mean target
Study
n = 52
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.8 +/- 2.2 yrAs given in this study (human).
Measurements
Above mean target height
41%
final height
Source sentences
Summary
A FH within TH range or in excess of mean TH was achieved by 78% or 41% of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the FH data of 52 young women from a prospective multicentric trial which was started in 1985.
Summary · context
Chronological age (CA) was 5.2 +/- 2.1 yr (+/- SD) at start of puberty, 6.2 +/- 2.0 yr at start of triptorelin depot treatment, 11.1 +/- 1.1 yr at end of treatment, and 16.7 +/- 2.6 yr at FH evaluation.
Report a problemFND-1096991703
04HumanNon-randomized trialEfficacy outcome
In young women treated with triptorelin, 29% had final height above the third percentile of the normal German population.
In plain wordsIn young women treated with triptorelin, 29% had final height above the German population's third percentile.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height above population third percentile
Study
n = 52
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.8 +/- 2.2 yrAs given in this study (human).
Measurements
Above third percentile
29%
final height
Source sentences
Summary
FH was above the 3rd percentile of the normal German population in 29% of patients (63% had an initial PAH < 156 cm).
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed the FH data of 52 young women from a prospective multicentric trial which was started in 1985.
Summary · context
Chronological age (CA) was 5.2 +/- 2.1 yr (+/- SD) at start of puberty, 6.2 +/- 2.0 yr at start of triptorelin depot treatment, 11.1 +/- 1.1 yr at end of treatment, and 16.7 +/- 2.6 yr at FH evaluation.
Report a problemFND-1096991704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.